Bitcoin News Update: Propanc’s Cryptocurrency-Driven Cancer Initiative Encounters Doubt from Investors, Stock Falls by 10.5%
- Australia-based Propanc Biopharma secured up to $100M from Hexstone Capital to build a crypto treasury and advance its cancer therapy PRP, targeting first-in-human trials by 2026. - The funding strategy reflects a growing trend in biotech to leverage crypto assets for non-dilutive capital, with Hexstone’s portfolio including Bitcoin , Ether , and Solana . - CEO James Nathanielsz called the move "transformative," aiming to diversify Propanc’s assets while tying capital to clinical milestones, though share
Headquartered in Australia,
This financing approach mirrors a rising trend among biotech companies turning to crypto treasuries as traditional capital markets become more challenging. Firms such as Sonnet BioTherapeutics and Sharps Technology have also embraced digital asset strategies to attract investors and diversify their funding streams
Hexstone Capital, which has supported other crypto treasury projects, has not specified which digital assets Propanc intends to purchase. Still, its holdings include Bitcoin (BTC), Ether (ETH),
The broader landscape for crypto treasury firms has encountered difficulties, with companies like Strategy and Metaplanet seeing notable drops in market capitalization
Propanc’s combined focus on cancer research and digital assets places it at the crossroads of two rapidly expanding industries. Preclinical studies of PRP have demonstrated a 70% reduction in tumor size in animal tests
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Breaking: Michael Saylor’s Strategy Expands Bitcoin Holdings to 641,692 BTC
HBAR price surges as Hedera joins Google BigQuery for transparent data access

CoreWeave's AI Surge Reaches $55B in Orders, Yet $12B in Capital Spending and Debt Raise Concerns Over Profitability
- CoreWeave reported $1.36B Q3 revenue (134% YoY) and $55.6B backlog, driven by AI cloud demand. - Stock fell 3.68% despite $12B 2025 CapEx, $110M net loss, and CEO selling $5.7M shares. - Partnership with CrowdStrike aims to secure AI infrastructure, but investors question profitability. - 2026 CapEx forecast at $28B raises concerns about converting $55.6B backlog into cash flow.

Top 5 Cryptos Soaring as U.S. Government Shutdown Ends